Table 2. Distribution of patients and parameters correlated with DMFS in validation set.
| Characteristic | No. | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | ||
| Tumor size (cm) | 0.055 | - | |||||
| ≤2 | 239 | 1 | - | ||||
| >2 | 308 | 1.45 | 0.99–2.12 | - | - | ||
| Unknown | 11 | ||||||
| Lymph node status | 0.293 | - | |||||
| Negative | 285 | 1 | - | ||||
| Positive | 231 | 1.23 | 0.84–1.81 | - | - | ||
| Unknown | 42 | ||||||
| TLS | 0.006 | 0.023 | |||||
| Low-risk | 380 | 1 | 1 | ||||
| High-risk | 178 | 1.66 | 1.15–2.40 | 1.54 | 1.06–2.24 | ||
| Intrinsic subtype | 0.057 | - | |||||
| Luminal A | 180 | 1 | - | ||||
| Others | 378 | 1.49 | 0.99–2.26 | - | - | ||
| Gene21 | 0.038 | 0.103 | |||||
| Low & medium-risk | 244 | 1 | 1 | ||||
| High-risk | 314 | 1.49 | 1.02–2.17 | 1.38 | 0.94–2.02 | ||
| Gene70 | 0.032 | 0.144 | |||||
| Low-risk | 94 | 1 | 1 | ||||
| High-risk | 464 | 1.90 | 1.05–3.45 | 1.58 | 0.86–2.92 | ||
DMFS=distant metastasis-free survival; HR=hazard ratio; CI=confidence interval; TLS=tamoxifen efficacy-related long noncoding RNA signature; Gene21=21-gene recurrence score; Gene70=70-gene prognosis signature.